13.63
Upstream Bio Inc Aktie (UPB) Neueste Nachrichten
What drives Upstream Bio Inc. stock priceOutstanding trading profits - jammulinksnews.com
Upstream Bio Inc. Stock Analysis and ForecastFree Stock Selection - jammulinksnews.com
What analysts say about Upstream Bio Inc. stockOutstanding capital returns - jammulinksnews.com
Is Upstream Bio Inc. a good long term investmentConsistent high-yield stocks - jammulinksnews.com
J.P. Morgan Maintains UpStream Bio(UPB.US) With Buy Rating - 富途牛牛
how upstream bio inc. stock performs during market volatilityFree Stock Market Insider Analysis - Newser
Upstream Bio, Inc. shares fall 4.98% premarket after HBM Healthcare Investments reports an 8.4% decline in NAV per share. - AInvest
What risks could impact Upstream Bio Inc. stock performanceHigh Potential Shares - Newser
Why Upstream Bio Inc. stock attracts strong analyst attentionHigh Return Conservative Stocks - Newser
How Upstream Bio Inc. stock performs during market volatilityFast Gains With Reduced Risk - Newser
Upstream Bio management to meet with Piper Sandler - TipRanks
What makes Upstream Bio Inc. stock price move sharplyFree VIP Investment Strategies - Newser
Will Q3 Shape Up To Be A VIBRANT Quarter For Upstream Bio? - RTTNews
Upstream Bio doses first patient in Phase 2 trial of verekitug in COPD - TipRanks
Upstream Bio, Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease - MarketScreener
Upstream Bio announces first patient dosed in phase 2 clinical trial of Verekitug - MarketScreener
Upstream Bio begins phase 2 COPD trial for verekitug - Investing.com
Upstream Bio Initiates Phase 2 VENTURE Trial for Verekitug in Moderate-to-Severe COPD, Expanding Its Respiratory Portfolio - Nasdaq
Upstream Bio Announces First Patient Dosed in Phase 2 - GlobeNewswire
Breakthrough COPD Drug Trial Launches with Unique 24-Week Dosing Schedule, Targeting 670 Patients - Stock Titan
Upstream Bio, Inc.(NasdaqGS: UPB) dropped from Russell 3000 Growth Index - MarketScreener
Rhumbline Advisers Has $82,000 Stock Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Upstream Bio Plunges 11.54% Amid Clinical Trial Data Anticipation - AInvest
Upstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody Space - TipRanks
Upstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher Potency - Asianet Newsable
Upstream Bio announces presentation of data on verekitug’s TSLP receptor - TipRanks
Translational Data Illustrate a Mechanism of Greater - GlobeNewswire
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor - The Manila Times
Upstream Bio Presents Pharmacology Modeling Data Supporting Verekitug's Potency over Tezepelumab at EAACI Congress - Nasdaq
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor - GlobeNewswire Inc.
Bank of America Corp DE Takes Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Upstream Bio Holds 2025 Annual Stockholders Meeting - TipRanks
Better Energy Stock: TotalEnergies vs. Chevron - The Globe and Mail
Upstream Bio (NASDAQ:UPB) Raised to Hold at Wall Street Zen - Defense World
Nuveen Asset Management LLC Takes Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Upstream Bio, Inc. to Present TSLP Receptor Targeting Data for Verekitug at EAACI Congress 2025 - Nasdaq
Upstream Bio to Present Mechanistic Insights into - GlobeNewswire
Breakthrough: Upstream Bio's Verekitug Demonstrates Enhanced Potency Over Current Asthma Treatments - Stock Titan
Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times
Upstream Bio to Reveal Latest Inflammatory Disease Treatment Progress at Major Goldman Sachs Conference - Stock Titan
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):